Company Overview

LIR Life Sciences Corp. is an over-the-counter traded company associated with the ticker SKNY. Based on publicly available corporate disclosures and historical market records, the company has been linked to the life sciences and dermatology-related product sector, with activities historically centered on skin health technologies, topical formulations, and commercialization initiatives tied to personal care and therapeutic applications. Publicly available information suggests the company has pursued intellectual property development and licensing opportunities connected to skin treatment technologies and consumer wellness products.

The company appears to have evolved through multiple corporate and strategic transitions over time, including changes in branding, business focus, and operating direction that are common among micro-cap OTC issuers. However, current operational details, audited financial visibility, and active commercial scale are limited in recent public disclosures. Data regarding current revenue composition, active products, and long-term operating strategy is inconclusive based on available public sources.

Business Operations

Historical disclosures indicate that LIR Life Sciences Corp. operated through activities tied to dermatological and topical health-related products, potentially including proprietary formulations, licensing arrangements, and commercialization partnerships. Public filings and OTC disclosures suggest the company’s business model relied more heavily on intellectual property development and strategic commercialization rather than large-scale manufacturing infrastructure. Information regarding active operating segments, recurring revenue streams, or geographically segmented reporting is limited.

There is insufficient current public information to conclusively identify active international operations, material subsidiaries, or major joint ventures. Publicly accessible records also do not clearly establish the existence of large-scale production assets, distribution networks, or significant institutional partnerships. Data inconclusive based on available public sources.

Strategic Position & Investments

Historically, the company’s strategic positioning appears to have focused on niche opportunities within skin care technology and life sciences commercialization. Available records suggest an emphasis on proprietary formulations and potential licensing opportunities tied to dermatological applications. As with many OTC-listed micro-cap issuers, strategic direction may have evolved over time depending on financing conditions, management changes, and market opportunities.

No major recent acquisitions, institutional investment programs, or large-scale portfolio holdings could be conclusively verified through broadly available public disclosures. Similarly, there is limited verifiable information regarding emerging technology initiatives, material research programs, or active investment activity in adjacent health-science sectors. Data inconclusive based on available public sources.

Geographic Footprint

Public records indicate the company has primarily operated within the United States, with its securities quoted on U.S. over-the-counter markets. Historical references suggest business activity and commercialization efforts may have targeted broader consumer and health-related markets, but verified evidence of extensive multinational operations remains limited.

There is no clearly verifiable evidence from recent public disclosures demonstrating a substantial operational footprint across Europe, Asia-Pacific, Latin America, or other major international regions. Information concerning foreign subsidiaries, overseas production facilities, or international investment exposure is inconclusive based on available public sources.

Leadership & Governance

Publicly available information regarding the company’s current executive leadership and governance structure is limited and appears inconsistent across historical records, OTC disclosures, and legacy filings. As a result, several leadership details could not be conclusively verified through reliable public documentation.

Available historical disclosures have referenced executive and management personnel associated with prior operational phases of the company, but current leadership roles may have changed and could not be independently confirmed with sufficient reliability. Data inconclusive based on available public sources.

• Data inconclusive based on available public sources � Current Chief Executive Officer
• Data inconclusive based on available public sources � Current Chief Financial Officer
• Data inconclusive based on available public sources � Current Board Leadership or Executive Officers